Login / Signup

The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network 'Rete Ematologica del Lazio per i Linfomi' (RELLI).

Ombretta AnnibaliStefan HohausFrancesco MarchesiMaria CantonettiAlice Di RoccoValeria TomarchioArianna Di NapoliSabrina PellicciaRoberta BattistiniPaola Anticoli BorzaElisabetta AbruzzeseNatalia CenfraAlessandro AndrianiCristiano TeseiEleonora AlmaFrancesca PalombiLivio PupoLuigi PetrucciMarco BecilliElena MaioloSilvia BellesiAnnarosa CuccaroFrancesco D'AlòMaria Christina Cox
Published in: Leukemia & lymphoma (2019)
In solid tumors and lymphomas, the neutrophil/lymphocyte (N/L) ratio at diagnosis has been shown to be a prognostic factor. The aim of our study was to validate the originally reported N/L ratio cut-point of 3.5 in patients with diffuse large B-cell lymphoma (DLBCL) registered in an Italian real-life database. The prognostic role of the N/L ratio at diagnosis on event-free survival (EFS) and overall survival (OS) was assessed in 505 patients with DLBCL. Patients with an N/L ratio <3.5 (n = 249) had a 4-year EFS probability of 76% and OS probability of 86%, significantly higher than the 4 year EFS rate of 48% and OS rate of 64% in patients with N/L ratio ≥3.5 (n = 256, both p<.0001). The N/L ratio was an independent prognostic factor in the multivariate analysis including the IPI score, and could separate patients with a low/intermediate risk IPI (IPI <3).
Keyphrases
  • diffuse large b cell lymphoma
  • prognostic factors
  • epstein barr virus
  • free survival
  • peripheral blood
  • adverse drug
  • electronic health record
  • drug induced
  • breast cancer risk